Validation of the PANAMA-Score for Survival and Benefit of Adjuvant Therapy in Patients with Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX

医学 叶黄素 胰腺癌 新辅助治疗 肿瘤科 胰腺切除术 内科学 辅助治疗 佐剂 癌症 外科 伊立替康 胰腺 结直肠癌 乳腺癌
作者
Ingmar F. Rompen,Thomas F. Stoop,Stijn van Roessel,Eran van Veldhuisen,Quisette P. Janssen,Adnan Alseidi,Alberto Balduzzi,Gianpaolo Balzano,Frederik Berrevoet,Morgan Bonds,Olivier R. Busch,Giovanni Butturini,Ammar A. Javed,Marco Del Chiaro,Kevin C. Conlon,Massimo Falconi,Isabella Frigerio,Giuseppe Fusai,Johan Gagnière,Oonagh Griffin
出处
期刊:Annals of Surgery [Lippincott Williams & Wilkins]
标识
DOI:10.1097/sla.0000000000006650
摘要

To validate the prognostic value of the PAncreatic NeoAdjuvant MAssachusetts (PANAMA)-score and to determine its predictive ability for survival benefit derived from adjuvant treatment in patients after resection of pancreatic ductal adenocarcinoma (PDAC) following neoadjuvant FOLFIRINOX. The PANAMA-score was developed to guide prognostication in patients after neoadjuvant therapy and resection for PDAC. As this score focuses on the risk for residual disease after resection, it might also be able to select patients who benefit from adjuvant after neoadjuvant therapy. This retrospective international multicenter study is endorsed by the European-African Hepato-Pancreato-Biliary Association (E-AHPBA). Patients with PDAC who underwent resection after neoadjuvant FOLFIRINOX were included. Mantel-Cox regression with interaction analysis was performed to assess the impact of adjuvant chemotherapy. Overall, 383 patients after resection of PDAC following neoadjuvant FOLFIRINOX were included of whom 187 (49%), 137 (36%), and 59 (15%) had a low-risk, intermediate-risk, and high-risk PANAMA-score, respectively. A discrimination in median OS was observed stratified by risk groups (48.5, 27.6, and 22.3 months, Log-Rank-Plow-intermediate=0.004, Log-Rank-Pintermediate-high=0.027). Adjuvant therapy was not associated with an OS difference in the low-risk group (HR 1.50, 95%CI:0.92-2.50), whereas improved OS was observed in the intermediate (HR 0.58, 95%CI:0.34-0.97) and high-risk groups (HR 0.47, 95%CI:0.24-0.94) (p-interaction=0.008). The PANAMA 3-tier risk groups (low-risk, intermediate-risk, and high-risk, available via pancreascalculator.com) correspond with differential survival in patients with resected PDAC following neoadjuvant FOLFIRINOX. The risk groups also differentiate between survival benefit associated with adjuvant treatment, with only the intermediate- and high-risk groups associated with improved OS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
还好完成签到,获得积分10
刚刚
sand发布了新的文献求助10
1秒前
mxq完成签到,获得积分10
1秒前
1秒前
3秒前
小柒完成签到,获得积分10
3秒前
3秒前
赘婿应助周老八采纳,获得10
4秒前
4秒前
leksj发布了新的文献求助10
5秒前
小柒发布了新的文献求助10
5秒前
6秒前
6秒前
7秒前
YMM关闭了YMM文献求助
7秒前
Owen应助sure采纳,获得10
7秒前
7秒前
大模型应助海藻采纳,获得10
8秒前
hufan2441发布了新的文献求助10
9秒前
chiu发布了新的文献求助20
9秒前
11秒前
友好坤发布了新的文献求助10
11秒前
睡不醒发布了新的文献求助10
12秒前
晨曦发布了新的文献求助10
12秒前
飞飞飞123发布了新的文献求助10
12秒前
wds发布了新的文献求助10
13秒前
田yg完成签到,获得积分10
13秒前
15秒前
勤恳的雅青完成签到,获得积分10
15秒前
hufan2441完成签到,获得积分10
15秒前
15秒前
16秒前
精明翠曼完成签到,获得积分10
16秒前
16秒前
赘婿应助耍酷的芝麻采纳,获得10
17秒前
FashionBoy应助小猴子采纳,获得10
18秒前
爆米花应助maohui采纳,获得10
19秒前
请叫我风吹麦浪应助jxwxxxx采纳,获得10
19秒前
19秒前
20秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 1370
生物降解型栓塞微球市场(按产品类型、应用和最终用户)- 2030 年全球预测 1000
Statistical Analysis of fMRI Data, second edition (Mit Press) 2nd ed 500
Lidocaine regional block in the treatment of acute gouty arthritis of the foot 400
Ecological and Human Health Impacts of Contaminated Food and Environments 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
International Relations at LSE: A History of 75 Years 308
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3932956
求助须知:如何正确求助?哪些是违规求助? 3477753
关于积分的说明 10998957
捐赠科研通 3208127
什么是DOI,文献DOI怎么找? 1772715
邀请新用户注册赠送积分活动 860008
科研通“疑难数据库(出版商)”最低求助积分说明 797433